Author:
Anglaret Siriane,Hilmi Marc
Reference10 articles.
1. Incidence des principaux cancers en France métropolitaine en 2023 et tendances depuis 1990;Lapôtre-Ledoux;Bull Epidemiol Hebd,2023
2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011
3. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial;Goldstein;JNCI,2015
4. 1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial;Ohba;Anal of Oncol,2023
5. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy;Drummond;Cancer Res,2006